JP2019116441A5 - - Google Patents

Claims (19)

And one or more lectins or fragments thereof are expressed on the surface of the vesicle or conjugate, if necessary viewing contains a drug,
The lectin or fragment thereof is a cation-dependent mannose-6-phosphate receptor (M6PR), P-selectin, E-selectin, L-selectin, P-selectin-ligand-1 (PSGL-1), CD22, CD206. , Galectin 3, anexin V, CD31, integrin αLβ2, VE-cadherin, CD44, CD300a, CD47, thrombospondin 1 (TSP1) and CD36, and a first protein selected from the group consisting of fragments thereof.
Protein-conjugated vesicles. Containing one or more lectins or fragments thereof expressed or conjugated to the surface of the vesicle and, if necessary, a drug.
The lectin or fragment thereof comprises a second protein selected from the group consisting of CD300a, CD47, thrombospondin 1 (TSP1), CD36 and Toll-like receptor 4 (TLR4) and fragments thereof.
Protein-conjugated vesicles. The vesicle according to claim 1 or 2, wherein the drug is encapsulated in the vesicle or added to the outer surface of the vesicle. The vesicle according to any one of claims 1 to 3 , which is a liposome or a micelle. The vesicle according to any one of claims 1 to 4, which can be artificially modified or derived from a cell. Wherein one or a plurality of first protein, and said one or more second proteins described in claim 2, vesicle according to any one of claims 1, 3 to 5 .. The vesicle according to any one of claims 1 , 3 to 5 , which comprises M6PR in combination with P-selectin, E-selectin, PSGL-1 or galectin-3. The vesicle according to any one of claims 1 , 3 to 5 , which comprises Sigma2 in combination with P-selectin, galectin-3 or CD31. The vesicle according to any one of claims 1 , 3 to 5 , which comprises P-selectin or M6PR in combination with TLR4, galectin-3, CLEC2, integrin αLβ2 or CD31. The drug is a diagnostic contrast agent, cell survival enhancer, cell survival inhibitor, cell component, organella, cell, cytotoxic drug, antitumor drug, toxin , antibody, lipid, protein, DNA, RNA, therapeutic agent or The vesicle according to any one of claims 1 to 9 , which is a nanomaterial. The soluble form, corresponding ligand is selected from neutralizing antibodies and blocking antibodies, antagonists of the first protein and the second protein,
To tissues containing autophagy cells and / or apoptotic cells, as well as autophagy cells and / or apoptotic cells
The vesicle according to any one of claims 6 to 10, which can act as a detoxifier for reducing vesicle targeting. And vesicle according to any one of claims 1 to 11, pharmaceutically and a acceptable carrier, a pharmaceutical composition. Autophagy cells and / or apoptotic cells, as well as for tissue containing said cells,
For delivering a drug, pharmaceutical composition according to claim 12. The pharmaceutical composition according to claim 12 or 13, wherein another autophagy inducer and / or an apoptosis inducer is administered to the subject before administering the pharmaceutical composition . A therapeutic or diagnosis of a disease associated with deregulated Oh Tofaji The pharmaceutical composition according to any one of claims 12 to 14. The diseases associated with autophagy deregulation include trauma, exposure to chemical and physical toxic factors, hereditary diseases, aging-related diseases, cardiovascular diseases, infectious diseases, neoplastic diseases, neurodegenerative diseases, metabolism. 15. A sexually transmitted disease, aging, obesity, cancer, β-amyloid or α-synuclein or a toxic-induced neurodegenerative, myopathic state, or chronic lung inflammation caused by cystic fibrosis. Pharmaceutical composition . A therapeutic or diagnostic of a disease caused by changes in apoptosis, a pharmaceutical composition according to any one of claims 12 to 14. The diseases associated with changes in apoptosis include trauma, exposure to chemical and physical toxic factors, hereditary diseases, aging-related diseases, aging-related diseases, cardiovascular diseases, infectious diseases, neoplastic diseases, and neurodegenerative diseases. , Metabolic disease, aging, obesity, cancer, β-amyloid or α-synuclein or toxic-induced neurodegeneration, muscle degeneration, or chronic lung inflammation caused by cystic fibrosis, or autoimmune disease The pharmaceutical composition according to claim 17 . The neurodegenerative disease is Alzheimer's disease , Parkinson's disease , Huntington's disease , muscular atrophic lateral sclerosis or stroke, and the cardiovascular disorder is ischemic, heart failure or infectious disease, and the autoimmune disease. The pharmaceutical composition according to claim 16 or 18 , wherein is systemic lupus erythematosus, autoimmune lymphoproliferative syndrome, rheumatoid arthritis or thyroiditis.